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Microfluidic label-free selection of mesenchymal
stem cell subpopulation during culture expansion
extends the chondrogenic potential in vitro†
Lu Yin, ‡a Yingnan Wu,‡b Zheng Yang,bc Ching Ann Tee,bc Vinitha Denslin,bc
Zhangxing Lai,d Chwee Teck Lim, aef Eng Hin Lee*bc and Jongyoon Han *ag
Mesenchymal stem cells (MSCs) have been shown as potential candidates for cell-based therapies for a
diverse range of tissue regenerative applications. Therapeutic use of MSCs usually requires culture expan-
sion, which increases the heterogeneity of MSCs in vitro, thus affecting the potency of the MSCs for more
specific indications. The capacity for identifying and isolating special subsets of MSCs for treatment of spe-
cific diseases therefore holds great clinical significance. An important therapeutic application of MSC is for
the regeneration of cartilage tissue. We and others have previously developed label-free microfluidic means
to isolate subpopulations of culture expanded MSCs based on distinct biophysical characteristics. Here we
utilize a spiral micro-channel device to separate culture expanded MSCs into five subgroups according to
cell size, and study their proliferation and chondrogenesis at early, middle and late passages. Results show
that in all passages, the medium-size subpopulation (cell size of 17–21 μm), compared to other subpopula-
tions, displays significantly higher proliferation rate and chondrogenic capacity in terms of cartilage extra-
cellular matrix formation. Also, the small cell subpopulation (average cell size of 11–12 μm) shows lower
viability, and large cell subpopulation (average cell size 23–25 μm) expresses higher level of senescence-
associated β-galactosidase. Finally, we show that repeated microfluidic exclusion of MSCs larger than 21
μm and smaller than 17 μm at every passage during continuous culture expansion result in selected
MSCs with faster proliferation and better chondrogenic potential as compared to MSC derived from con-
ventional expansion approach. This study demonstrates the significant merit and utility of size-based cell
selection for the application of MSCs in cartilage regeneration.
Introduction
Human mesenchymal stem cells (MSCs) have long been con-
sidered as promising candidates in tissue regenerative
therapies.1–3 MSCs not only function as self-renewable
multipotent stem cells to replace damaged tissue,4,5 but also
regulate immune responses to limit immune mediated disor-
der6,7 and produce bioactive molecules to promote tissue re-
generation.8,9 Numerous studies have shown the potential of
MSCs in the treatment of a diverse range of diseases.10–24
Clinical use of MSCs usually requires extensive culture
expansion to acquire therapeutically relevant numbers, re-
gardless of whether the cells function through direct engraft-
ment or via its trophic factors,25 because the yield from pri-
mary tissue is insufficient.26 Studies on MSC expansion have
mainly focused on the viability27–29 and scalability30–32 of the
cells, however, culture expanded MSCs have been shown to
be morphologically and functionally heterogeneous.33 The
in vitro heterogeneity may be implicitly related to the inher-
ent phenotype and potency variability of MSCs derived from
different tissue microenvironments,34 which could have
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further perpetuated under different culture conditions.35
Studies have suggested that subgroups of MSCs with specific
potency or production of specific secretome could be more
therapeutically effective in the regeneration of specific tis-
sues, when compared to the total heterogeneous popula-
tion.36,37 Thus, the potential of generating large quantities of
MSCs manipulated towards specific states for treatment of
specific diseases holds great clinical significance.
The need for large quantities of MSCs enhanced with
strong chondrogenic potential for therapeutic use is compel-
ling. MSC-based cartilage regeneration is one of the most
well-established therapeutic applications, for the treatment of
trauma-induced cartilage lesion, as well as degenerative oste-
oarthritic cartilage.38,39 Cell numbers required for implanta-
tion in cartilage repair are large, mostly in the range of
millions to a hundred million,40 which entail extensive ex-
pansion. However, as MSCs grow larger over time during ex-
pansion,41 there is a tendency of decreasing chondrogenic
potential.42 As a result, the therapeutic efficacy of MSCs for
regenerating cartilage would greatly benefit from manipulat-
ing them towards “chondrogenic competent” state during ex-
tensive culture expansion.
A seemingly straightforward way to achieve this is to in-
duce MSC commitment to the desired state, however it is
practically difficult, not only because of the tight restrictions
on chemical treatment to MSCs for therapeutic use, but also
because the favourable states of MSCs for different therapeu-
tic uses are difficult to standardise and maintain in culture.
An alternative approach is to isolate the “chondrogenic com-
petent” subpopulation of MSCs from the heterogenous popu-
lation after culture expansion. We and others have previously
characterized MSC subpopulations using biophysical parame-
ters,42,43 and developed high-throughput label-free micro-
fluidic technique for the isolation of MSC subpopulations
based on cell size differences.36,44 However, the remaining
problem is the uncertainty in the ratio of targeted subpopula-
tion cell numbers to the total population cell numbers at the
end of culture expansion. It is very likely that the
“chondrogenic competent” subpopulation would drastically
reduce due to the increasing heterogeneity along with exten-
sive expansion41,42 which overwhelms the culture conditions.
A possibly more efficacious approach is to enrich the
“chondrogenic competent” subpopulation over the extended
expansion period by repeated subpopulation selection, to
maintain the homogeneity of culture throughout expansion
process.
The first step of this approach was to identify the subpop-
ulation of MSCs that's “chondrogenic competent”. We first
separated culture expanded human bone marrow-derived
MSCs into five size-dependent subgroups through serial
sorting using a spiral micro-channel device,36,45 based on
Dean flow fractionation principle.46–48 Briefly, cells flowing in
micro-channel experience shear-induced and wall-induced lift
forces in the cross-sectional plane perpendicular to the flow
direction. The spiral geometry of the micro-channel adds a
Dean drag force to the cells due to centrifugal acceleration.
As a consequence of the lift and drag forces, while the cells
flow through the spiral micro-channel, they also migrate on
the cross-sectional plane of the channel, and reach an equi-
librium position where the net force is zero. This equilibrium
position is determined by cell size when other conditions
(such as channel dimensions, flow rate, density and viscosity
of the medium, etc.) are fixed. Also, the equilibrium position
of a cell alters when it flows through the spiral micro-
channel at different flow rates. This principle enabled us to
use a spiral micro-channel device with two outlets to sort five
size-dependent subgroups of MSCs one at a time at different
flow rates. We then profiled the proliferation and chondrog-
enesis capacity of each subgroup at early, middle and late
passages during culture expansion, and identified the
“chondrogenic competent” subpopulation by considering the
chondrogenic capacity, proliferation rate, as well as the ratio
of cell number in the subpopulation to total population. This
subpopulation was selectively expanded using the spiral
micro-channel device to remove other MSCs of bigger or
smaller size range from the culture repeatedly at every pas-
sage/subculture over 2 month culture expansion period. The
efficacy of this selective expansion to enrich proliferative
“chondrogenic competent” MSC was compared to normal ex-
pansion approach. We found that the most competent MSCs
for cartilage repair were medium-size cells in culture between
17 to 21 μm, and selective expansion maintained the prolifer-
ation rate and chondrogenic potential of the expanded cells
for significantly prolonged culture period, and produced
higher cell yield as compared to the normal MSC culture ex-
pansion approach.
Materials and methods
MSC culture
Bone marrow derived human MSCs were purchased from
Lonza Pte. Ltd. (Lonza PT 2501) and RoosterBio Inc. MSCs
from four donors (Lonza Lot no. 000047198, 0000482966 and
0000483199, RoosterBio Lot no. 00022) were culture ex-
panded in DMEM with 1% Glutamax, 10% FBS, 1% Pen
Strep, and 1 ng ml−1 FGF-2 (Thermo Fisher Scientific Pte.
Ltd., Singapore) from the original vial for 6–7 doublings be-
fore cryopreservation. The cryopreserved cells were then
thawed and culture expanded in 175 cm2 cell culture flask
(Thermo Fisher Scientific Pte. Ltd., Singapore) at seeding
density of 1.14 × 103 cell per cm2. Since continuous culture
expansion of MSCs started from 6–7 doublings in this study,
we define MSCs underwent 8–10 total doublings in culture as
“early passage”, 13–15 doublings as “middle passage”, 18–20
doublings as “late passage” (all doubling numbers were
counted by denoting the cells from the original commercial
source as 0 doubling). The population doubling number (PD)
was estimated from the formula n = 3.32 × (log EC − log IC) +
X, where n is the PD at end of a given subculture, EC is the
cell count at end of subculture, IC is the cell count at begin-
ning of subculture, and X is the PD at beginning of
subculture.
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MSCs were harvested at 90% confluency for assays and
subcultured by 2 minute incubation with 0.05% trypsin-EDTA
(Thermo Fisher Scientific Pte. Ltd., Singapore) at 37 °C. The
cell count and viability were measured using disposable
haemocytometer (INCYTO Co. Ltd. Korea) after 1 : 1 mixing
with Trypan Blue (Thermo Fisher Scientific Pte. Ltd., Singa-
pore). The seeding density used for subculture was 1.14 × 103
cell per cm2.
MSC colonies were formed by seeding unsorted (S0) and
sorted subgroups (S1–5) of MSCs in 6-well plate at seeding
density of 500 cell per well. After 5 days culture, the colonies
formed was Giemsa stained and counted under light micro-
scope. The colony forming efficiency (CFE), defined as the
percentage of cells inoculated at low density that give rise to
colonies, was then calculated as CFE = Nc/Ni × 100%, where
Nc is the number of colonies formed, Ni is the number of
cells inoculated.
Formation of cartilage pellet was achieved by seeding
MSCs in U-bottom 96-well plate (NEST Biotechnology Co.
Ltd. China) with 200 μl of chondrogenic medium (high glu-
cose DMEM supplemented with 10−7 M dexamethasone 1%
ITS+ Premix supplement 50 mg ml−1 ascorbic acid 1 mM so-
dium pyruvate and 4 mM proline and 10 ng ml−1 TGFβ-3)49
at density of 105 cell per well and centrifuged at 300g for 5
minutes. Medium was changed every alternative day for 3
weeks before the pellets were imaged and weighed.
Spiral micro-channel device design and fabrication
The spiral micro-channel device was designed and fabricated
in the same way as previously described.45 Briefly, it was
casted from polydimethylsiloxane (10 : 1 mixture of base and
curing agent. Sylgard 184, Dow Corning Inc., USA) using a
micro-milled aluminium mold (Whits Technologies Inc., Sin-
gapore). The device had one inlet and two outlets and 8-loops
with radius decreasing from 12 mm to 4 mm (from inlet to
outlet). The cross-section of the channel was trapezoidal with
580 μm width, 85 μm/133 μm inner/outer height respectively
(Fig. 1A). The ratio of the inner outlet width to outer outlet
width was about 5 : 7. The inner to outer fluid ratio was about
1 : 2 at input rate of 1.5 mL min−1.
MSC sorting with spiral micro-channel device
Buffers and MSCs suspensions in 4 mL medium (0.2–1
million MSCs per mL) were loaded in syringes (Thermo
Fisher Scientific Pte. Ltd., Japan), and connected to the inlet
of spiral micro-channel device with precision tips (Nordson
Corp. USA) and Tygon tubing (Spectra Teknik Pte, Ltd, Singa-
pore). Tygon tubings were also connected to the two outer
outlets for collection of sorted subgroups. A syringe pump
(PHD 2000, Harvard Apparatus Inc., USA) was used for accu-
rate pumping. Before sorting, 1% poloxamer 188 (Sigma-
Aldrich Co. LLC. Singapore) in Milli-Q water was pumped
into the spiral micro-channel device for 2 min at 1 mL min−1
to prevent cell sticking followed by 1× PBS to wash off the
water.
In the MSC subgroup characterization experiment, MSCs
at each passage were first pumped into the device at 4 mL
min−1, and subgroup S5 was collected from the inner outlet.
Then subgroups S4, S3 and S2 were sequentially collected
from the inner outlet by pumping the MSCs collected from
outer outlet back into the device at 3.5 mL min−1, 2.5 mL
min−1, and 1.5 mL min−1 respectively. In the last round of
sorting at 1.5 mL min−1, subgroup S1 was collected from the
outer outlet while S2 was collect from inner (Fig. 1B).
In the selective MSC culture expansion experiment, MSCs
were expanded normally to passage 3, and then the same
number of cells were cultured in parallel using either selective
culture expansion or conventional culture expansion up to
passage 10 in 2 months. For selective MSC culture, cells at
each passage were first pumped into the device at 3.5 mL
min−1 to remove large cell population (>21 μm) from the in-
ner outlet. MSCs collected from the outer outlet were
pumped through the device again at 1.5 mL min−1 to further
remove small cell population (<17 μm) from the outer outlet
(Fig. 6A).
Real-time cell separation within the spiral micro-channel
device was recorded by an inverted microscope (IX71, Olympus
Co., Japan) equipped with a high-speed CCD camera (Phantom
v9, Vision Research Inc., USA). The recorded sorting videos
were processed for snapshot images using ImageJ software
(NIH, USA).
Estimation of theoretical total MSC yield after continuous
culture expansion
In the selective MSC culture expansion experiment, only a
fraction (0.5–1 million) of harvested MSCs were passaged for
subculture, and the theoretical total cell yield (TTC), assum-
ing all cells were passaged, was estimated from the formula
c = EC × Y/IC × α, where c is the TTC at the end of a passage,
EC is the cell count at the end of a give subculture, Y is the
TTC at the end of previous passage, IC is the cell count
seeded at the beginning of the subculture, α is the propor-
tion of 17–21 μm MSC over the total number of MSC at this
passage. The value of α equals to 1 when MSCs are cultured
without subpopulation selection, and equals to the recovery
rate of 17–21 μm MSCs at each passage (Table S2†) during se-
lective culture expansion.
MSC size analysis
MSCs were measured by Moxi Z Mini automated cell counter
with type M cassette (Orflo Technologies Inc., USA). MATLAB
(The MathWorks Inc., USA) was then used to calculate the
statistics from the original CSV files generated by the cell
counter. MSCs with measured diameter less than 8 μm were
considered as artifacts and excluded from study. An imaging-
based MATLAB algorithm using circle Hough Transforms to
identify cells (developed by Prof. Krystyn Van Vliet's group
from MIT) was also used to measure MSC sizes, and validate
the readings from Moxi Z Mini (Table S1†).
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RT-PCR
RT-PCRs for collagen I (Col I), collagen II (Col II), collagen X (Col
X), aggrecan (Aggr), Ki-67, and GAPDH were conducted using the
SYBR green system according to previous published protocol.50
Expression of Col I, Col II, Col X, Aggr and Ki-67 were normal-
ized to GAPDH. Col I, Col II, Col X and Aggr were presented
as fold changes with reference to the undifferentiated MSCs.
Histology staining
Formalin fixed cartilage pellet samples were dehydrated with
xylene, and embedded in paraffin blocks. Sections of 5 μm
thickness were cut with a microtome, and mounted on
polylysine-coated slides. The paraffin sections were de-waxed
and rehydrated in ethanol using standard protocol before
staining. For detection of chondrogenesis, the sections were
stained with Alcian Blue (Sigma-Aldrich Pte. Ltd., Singapore)
for 30 minutes, washed with 1× PBS and counter-stained with
Nuclear Fast Red (Sigma-Aldrich Pte. Ltd., Singapore) for 5
minutes.
Senescence assay
Unsorted MSCs (S0) and sorted subgroups (S1–5) were cul-
tured in 6-well plate for 3–4 days at seeding density of 3 × 104
cell per well. Senescence β-galactosidase staining kit (Cell Sig-
nalling Technology, USA) was used to stain the cells
according to the manufacturer's guide. The cells were then
stained for nucleus with Hoechst 33 253 solution (Thermo
Fisher Scientific Pte. Ltd., USA, Cat. no. 86145) at 1 μg mL−1
Fig. 1 Isolation of size-dependent MSC subgroups with spiral micro-channel device. (A) Schematic of an 8-loop spiral micro-channel device with
trapezoidal cross-section. (B) Flow chart of MSC inertial sorting strategy. Culture expanded MSCs are sequentially separated into five subgroups,
S5–S1 with decreasing size, by four rounds of sorting at different flow rates. Colored spheres represent MSCs with various sizes. (C) Phase contrast
images captured by high speed camera on separation of MSC subgroups at the branching point before the outlets of the spiral micro-channel de-
vice. Arrows indicate the S1–S5 subgroups being isolated at different flow rates.
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in PBS for 5 min in dark. An inverted microscope (U-TB 190,
Olympus Co., Japan) equipped with a CCD camera (Retiga
2000R, Qimaging Inc., Canada.) was used to capture bright
field images with senescence staining (the green colour pre-
cipitate resulted from cleavage of X-gal substrate) and fluores-
cent images with nucleus staining at the same spot. Five to
ten random spots were imaged for each subgroup, and the
images were processed with MATLAB (The MathWorks Inc.,
USA) for computing the senesces index (SI). SI was defined as
the average level of senescence signal per cell in all images
taken from the same subgroup. The senescence staining ap-
peared to be green/blue colour in the bright field images, and
the level of greenness/blueness indicated the level of senes-
cence. The positive staining areas in the images were
reflected as areas lack of red color component. Thus, the pos-
itive staining areas were selected based on the criteria that
the red color intensity in the area was lower than 65 (maxi-
mum 255 in unit8 RGB image format), and lower than both
green and blue content; meanwhile, green and blue color
intensities are higher than 50. Extremely small areas fulfilling
the criteria were ignored as artefacts. Next, the total level of
senescence in an image was calculated as the sum of the
complement of red intensity (255 – red intensity) in all the se-
lected areas. The total number of cells in the image was com-
puted based on the number of Hoechst positive areas in the
corresponding fluorescent image. Then SI of the image was
computed as the ratio of total senescence level to the total
cell number in the image. The final SI of a subgroup of MSCs
was normalized by subtracting the SI of the total MSCs at the
beginning of the culture expansion.
FACS-based cell cycle analysis
Unsorted MSCs (S0) and sorted subgroups (S1–5) were
suspended in 500 μl 1× PBS at 0.1 million cells per mL. Five
μl of 50× SYBR green stain (Thermo Fisher Scientific Pte.
Ltd., USA, Cat. no. S7563) were added to the suspension and
incubated on ice for 15 min in dark. The stained cells were
then washed with 1 mL 1× PBS for three times and filtered
with 40 μm Nylon mesh cell strainer (Thermo Fisher Scien-
tific Pte. Ltd., China) before loading to Accuri C6 flow
cytometer (BD biosciences, Singapore). Ten thousand events
were recorded for each measurement, and green fluorescence
signal was detected as a measurement of DNA content. Flow
data were processed by CFlow Plus software (BD biosciences,
Singapore) for analysing cells under mitosis.
Results and discussion
Microfluidic sorting of size-dependent MSC subgroups
To identify the most competent subpopulation of culture ex-
panded MSCs for chondrogenesis, total MSCs population at
early, middle and late passages (refer to Materials and
methods for the definition of early, middle and late passage)
were sorted respectively into five subgroups based on cell
size. Original population of MSCs (Pre-sorted, S0) were
pumped into a spiral micro-channel device (Fig. 1A), and the
subgroups (S1–S5, S1: smallest size) were sequentially col-
lected from the outlets of the device after four rounds of
sorting (Fig. 1B). Separation of the size-dependent MSC sub-
groups at the branching point of the spiral micro-channel
was recorded with high speed camera. The cell size difference
among the subgroups can be observed in the images
(Fig. 1C). Analysis showed that the average size of MSCs in-
creased from early to late passages, and the total MSCs were
successfully separated into subgroups with distinct size dif-
ferences (p < 0.05) at all passages (Fig. 2A). The biggest size
difference between adjacent subgroups was 5–7 μm, occurred
between S1 and S2; the smallest difference was 1–3 μm, be-
tween S4 and S5. All the cell sizes were measured using an
automated Coulter counter in this study. A comparison be-
tween the cell size measured by the Coulter counter and an
Fig. 2 Cell size and composition of size-dependent MSC subgroups. (A) Average sizes of total MSC (S0) and MSC subgroups (S1–5) at early, middle
and late passages during culture expansion. The three horizontal lines in each box represent first quartile, median, and third quartile. The error bars
represent standard deviations. The dots represent the means. Statistical significance is determined by Student's t-test, * indicates p < 0.05, ** indi-
cates p < 0.001. (B) Cell count composition of each subgroups in total population at early, middle and late passages during culture expansion.
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
Fe
br
ua
ry
 2
01
8.
 D
ow
nl
oa
de
d 
on
 7
/1
1/
20
18
 3
:5
2:
04
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Lab Chip, 2018, 18, 878–889 | 883This journal is © The Royal Society of Chemistry 2018
automated imaging-based algorithm is shown in Table S1.†
Majority of the MSCs belonged to subgroups S2 and S3, cor-
responding to average diameter of 17–21 μm, and comprising
60–70% of the total population in all passages. The composi-
tion of S2 and S3 decreased from early to late passage, while
S4 and S5 increased, which was consistent with the increas-
ing average cell size.
Profiling proliferation of size-dependent MSC subgroups
during culture expansion
The efficiency of producing MSCs in large quantity is deter-
mined by the proliferation rate of the cells. We assayed the
proliferation rate of the five sorted MSC subgroups in early,
middle and late passages by PCR analysis of proliferation
marker Ki-67 (Fig. 3A). Results showed that the proliferation
significantly reduced from middle to late passage, and was
mainly contributed by the decrease in subgroup S4 and S5.
Subgroups S1–3 had faster overall proliferation rate as com-
pared to S4 and S5 in all passages. Notably, proliferation of
S2 and S3 subgroups was maintained from early to late
passages.
Similar to the proliferation rate, colony forming efficiency
(CFE) of MSCs also decreased from 5% in early passage to
2% in late passage, and subgroups S1–3 had significantly
higher overall CFE comparing to S4 and S5 in all passages
(Fig. 3B). It was also observed that the subgroups with
highest CFE gradually shifted from S1 in early passage to S3
in late passage (Fig. 3B).
Profiling chondrogenesis of size-dependent MSC subgroups
during culture expansion
MSCs with stronger chondrogenic capacity are preferred in
the therapeutic use for cartilage repair. We investigated the
chondrogenic capacity of the sorted MSC subgroups in early,
middle and late passages by inducing chondrogenesis in pel-
let culture. We observed that S2 and S3 were able to form
spherical cartilage pellets in culture after 3 weeks. However,
S1, S4 and S5 either failed to form spherical pellets or formed
much smaller pellets (Fig. 4A). The sizes and weights of the
cartilage pellets were measured. Results showed that the pel-
lets formed by S2 and S3 were significantly larger and heavier
as compared to those of other subgroups over all passages
(Fig. 4B and C).
The cartilage pellets formed by different MSC subgroups
were processed for PCR and histology analysis on
chondrogenic markers. PCR results showed that the average
expression level of collagen II (Col II) and aggrecan (Aggr)
over all passages were significantly higher in S2 and S3 com-
paring to S1, S4 and S5 (Fig. 4D and E), which was consistent
with the observed difference in cartilage pellet sizes. Alcian
Blue staining on the cartilage pellet sections also indicated
the occurrence of chondrogenesis in all subpopulations of
MSCs, but significantly higher level of chondrogenesis in S2
and S3 (Fig. 4F). Collagen I (Col I) expressions in different
subgroups did not follow the same pattern as Col II or Aggr.
Col I expression was found to be similar in S1 to S4, but sig-
nificantly higher in S5, at all passage points (Fig. 4G). The ra-
tio of Col II to Col I in different subgroups followed similar
trend as Col II expression, with S2 and S3 being the highest
subgroups (Fig. S1A†). We further analysed the expression of
hypertrophic marker collagen X (Col X) in the cartilage pel-
lets. Significantly higher level of Col X was found in S5 in all
passages, and in S4 in the late passage (Fig. 4H). Chondro-
cyte hypertrophy is associated with enlarged cell size,50 which
is consistent with the larger size of MSCs in S5. The high Col
II, low Col I and Col X expression in S2 and S3 indicated for-
mation of more hyaline and less fibrous cartilage tissues in
these subgroups. The different trends in Col I, Col II and Col
X expression from S1 to S5 ruled out the possibility that ob-
served higher Col II in S2 and S3 was merely caused by
higher metabolic activity.
Analysis of viability and senescence of size-dependent MSC
subgroups
Characterization of the size-dependent MSC subgroups indi-
cated that the medium-size MSCs (S2 and S3), with average
size ranging from 17 to 21 μm, had faster proliferation rate
and chondrogenic capacity in all passages as compared to
the smaller (S1) and bigger (S4 and S5) MSCs. Both the prolif-
eration and differentiation of MSCs could be affected by the
Fig. 3 Proliferation of size-dependent MSC subgroups. (A) RT-PCR analysis on Ki-67 and (B) colony forming efficiency of total MCS (S0) and MSC
subgroups (S1–5) at early, middle and late passages during culture expansion. All error bars represent standard deviations. Statistical significance is
determined by Student's t-test, * indicates p < 0.05.
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cell viability and senescence,51 and studies have reported the
correlation of cell viability,52,53 as well as MSC senes-
cence,45,58 with cell size in culture.41,54 Thus, we investigated
the cell viability and senescence level in the size-dependent
Fig. 4 Chondrogenesis of size-dependent MSC subgroups. (A) Images of cartilage pellets formed by MSC subgroups after 3 weeks of differentia-
tion. Scale bar: 500 μm. (B and C) Measurement of cartilage pellet size (B) and weight (C) formed by total MSC (S0) and MSC subgroups (S1–5) at
early, middle and late passages. (D and E) RT-PCR analysis on Col II (D) and Aggrecan (E) level in cartilage pellet formed by MSC (S0) and sub-
groups (S1–5) at early, middle and late passages. (F) Alcian blue staining of cartilage pellets formed by MSC subgroups. Scale bar: 25 μm. (G and H)
RT-PCR analysis on Col I (G) and Col X (H) level in cartilage pellet formed by MSC (S0) and subgroups (S1–5) at early, middle and late passages. All
error bars represent standard deviations. Statistical significance is determined by Student's t-test, * indicates p < 0.05, ** indicates p < 0.001.
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subgroups in early, middle and late passages. Results showed
that average viabilities of each subgroup over all the passages
were greater than 90%, and no significant change in viability
was found from early to late passages. However, S1 has an av-
erage viability of 93% over all passages, which was signifi-
cantly lower than 98% in other subgroups (Fig. 5A).
Senescence-related β-galactosidase staining of MSCs sub-
groups at different passages was performed. It was observed
that the percentage of senescent cells increased from small
(S1) to big (S5) size, and from early to late passages (Fig. 5B).
The senescence level of MSCs was quantified as senescence
index (SI), which was computed as the amount of
senescence-related β-galactosidase staining per cell in culture
using an automated image processing algorithm (refer to Ma-
terials and methods). SI increased from early to middle, and
from middle to late passages (p < 0.05). In all passages, se-
nescent cells were not observed in S1; very few appeared in
S2 and increased from S3 to S5. Significantly higher level of
senescence was observed in S5 than the rest of the subgroups
in middle and late passages, indicating increase in the cell
size of aging cells (Fig. 5C). However, even in S5 of late pas-
sage MSC, not all the cells in S5 were senescent. FACS analy-
sis on the cellular amount of DNA showed that 25% of cells
in S5 were at G2/M phase of the cell cycle over all passages
(Fig. 5D and Fig. S2†), despite the overall reduction of divid-
ing cells from 19% in early passage to 10% in late passage
(Fig. S2†).
Selective MSC culture expansion with repeated microfluidic
subpopulation selection
To identify the most competent subpopulation of MSCs for
therapeutic use in articular cartilage repair, we considered
several properties of the cells. Firstly, this subpopulation
should possess strong chondrogenic capacity in order to dif-
ferentiate into chondrocytes and secrete corresponding
ECM to form hyaline cartilage tissue. Secondly, they should
proliferate to a large enough cell number needed therapeuti-
cally. Lastly, for technical applicability, this subpopulation
should account for enough high percentage of cell numbers
Fig. 5 Viability and senescence of size-dependent MSC subgroups. (A) Average viability of size-dependent MSC subgroups over all passages. (B)
Senescence index of size-dependent MSC subgroups. (C) Phase contrast images of size-dependent MSC subgroups with senescence staining at
different passages. Scale bar: 500 μm. (D) Average percentage of dividing cells in each size-dependent MSC subgroups over all passages. All error
bars represent standard deviations. Statistical significance is determined by Student's t-test, * indicates p < 0.05, ** indicates p < 0.001.
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in the total MSC population so as to be efficiently isolated
and expanded to adequate numbers for therapeutic use.
Our investigation concluded that the combination of
S2 and S3 MSC subgroups matched all three aspects
(Fig. 2B–4), indicating that the most competent MSCs for
cartilage repair are medium-size cells in culture between 17
to 21 μm (Fig. 2A). Colter et al. has identified an extremely
small-sized (7 μm) population of MSCs with stronger
multipotency than the normal-size MSCs (15–50 μm),42 and
Poon et al. has further suggested that smaller MSCs (15 μm)
are at multipotent state, whereas larger MSCs (20 μm) com-
mit towards osteoprogenitor state with reduced multi-
potency.36 The “chondrogenic competent” subpopulation we
identified fell in-between these sizes.
We next designed a simplified sorting strategy with the
same spiral micro-channel device to enrich MSCs of 17–21
μm from the total population by excluding the larger and
smaller cells respectively with two rounds of sorting (see Ma-
terials and methods). This sorting strategy was applied to
each subculture up to 10 passages as a “selective expansion”
approach to enrich only MSCs of high chondrogenic compe-
tence (Fig. 6A). MSCs from the selective expansion approach
were compared to normal expansion approach in terms of
population doubling time (PDT) and total cell yield within
same period of culture time.
Results showed that PDT of the MSCs with normal expan-
sion gradually increased from about 5 days to 26 days by pas-
sage 10, whereas PDT of the MSCs with selective expansion
remained below 11 days (Fig. 6B). In this experiment, MSCs
cultured with both methods were passaged at the same time
points for the convenience of comparison. Thus, the
confluency of normal culture expanded MSCs at every pas-
sage decreased gradually, as the difference in PDT of MSCs
between the cultures increased. The corresponding number
of days post initial seeding for every passage performed is
provided in Table S2.† The average recovery of 17–21 μm
MSCs decreased from 67% to 46% of total cells, with an aver-
age of about 60% (Table S2†).
As selective culture yielded shorter PDT than normal cul-
ture in all passages, we then calculated the theoretical total
MSC yield from the two culture expansion approaches (see
Materials and methods). The calculated result showed that
selective culture expansion led to approximately 33% more
cell yield comparing to the normal expansion by passage 10
(Fig. 6C).
Besides the actively excluded large and small MSCs, some
cells were lost during the sorting process. Part of the loss was
attributed to the dead-end volume of cell suspension in the
syringe, tubing, micro-channel, and collection tubes, espe-
cially during repeated transferring of cell suspension from
collection tubes to syringes for sorting (estimated to be ap-
proximately 5% of total cells). It was also possible that
weaker and unhealthy cells ruptured during the sorting pro-
cess due to hydraulic shear. Nevertheless, the selective cul-
ture expansion was able to produce more MSCs than the nor-
mal approach within the same period of time despite of the
cell loss (Fig. 6C). Higher cell yield could be achieved with
further refinement in sorting procedure. Higher percentage
of dividing cells was detected in S5 than other subgroups
(Fig. 5D). It was likely that some medium-size MSCs undergo-
ing division might have been removed together with the large
cells due to their transient expansion in cell size.
The chondrogenic potential of the MSCs expanded with
selective and normal expansion approach was also compared
at multiple passage points. PCR analysis showed that the
level of Col II gradually decreased to 29.5% of the original
level by passage 10 with the normal culture expansion, but
remained at 88.5% of the original level with selective culture
approach (Fig. 6D). Similarly, the level of Aggr dropped to
53.1% of the original level with normal culture expansion,
but remained at 79.8% with selective expansion (Fig. 6E). In
addition, comparing to the drastically increased Col I and rel-
atively higher Col X level by end of passage 10 under normal
culture expansion, the level of Col I only increased by 10%
(Fig. 6F), and Col X decreased to 36% under selective culture
expansion. Similar to Col II level, the Col II/Col I ratio also
reflected significant difference between the two culture
methods (Fig. S1B†). These results clearly demonstrated the
advantage of the selective expansion approach over normal
approach in maintaining the chondrogenic potential of MSC
during culture expansion.
Given that small and large MCSs that were recursively re-
moved from the culture comprised up to 30–40% of total
cells at each passage (Fig. 2B and Table S2†), the observed
enhancement in proliferation (PDT), total cell yield, and
chondrogenic potential of the new selective culture expansion
protocol is of high clinical significance and utility. Although
the biological mechanism of how the small and large MSCs
influence the medium-size MSCs in culture was not investi-
gated in detail, we noticed the difference in viability and se-
nescence among the populations. Dead cells were mainly ob-
served in the small (S1) MSC population (Fig. 5A), suggesting
their disadvantage in growth. However, the slightly lower via-
bility (93%) in small MSC population was unlikely the major
contribution to the slower growth and significantly weaker
chondrogenic capacity, compared to the selected medium-
size population. The large MSC population (S5) comprised of
more senescent cells than the small and medium-size popu-
lation (Fig. 5B and C), which could directly contribute to their
slow proliferation rate and weak differentiation capacity.55,56
It is highly likely that the secretome from the larger and
smaller MSC could have affected the state of the medium-
size cells. Reducing the potentially negative paracrine signal-
ling from unwanted subgroups might further help to main-
tain the homogeneity of the culture.
Advantages of the microfluidic selection approach over other
purification methods
Although other biophysical or biochemical approaches could
possibly be used to purify 17–21 μm MSCs as well, our micro-
fluidic approach possesses clear advantages in many aspects.
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Our approach is label-free and high-throughput as compared
to FACS. Being label-free eliminates the potential influences
of surface-labelling to the MSCs in therapeutic use, thus sim-
plifying the complexity and improving the compliance with
the regulations. In this study, we used about 1 million per
mL MSC concentration for the sorting, with minimum
sorting flow rate at 1.5 mL min−1, achieving high throughput
sorting of 1.5 million cells in a minute. Ultra-high through-
put can be achieved by multiplexing the spiral micro-channel
device to specially cater the need for purifying extremely large
Fig. 6 MSC selective culture expansion with repeated inertial sorting maintains proliferation rate and chondrogenic potential in late passages. (A)
Schematic of selective culture expansion strategy. MSCs were expanded normally in TCP and subcultured at 90% confluency. MSCs larger than 21
μm or smaller than 17 μm were excluded at every subculture and only 17–21 μm ones were passaged. (B) MSC population doubling time in normal
(black bar) and selective (white bar) culture expansion at each passage. (C) Total number of MSCs produced by normal (line with round dots) and
selective (line with triangle dots) culture expansion at different passages. The inconsistent gaps among the passage numbers in the x-axis represent
different days of culture among the passages. Corresponding days of culture post initial seeding at each passage is provided in Table S2.† (D–G)
RT-PCR analysis on Col II (D), aggrecan (E), Col X (F) and Col I (G) level in cartilage pellet formed by MSCs at different passages after normal (white
bar) and selective (black bar) culture expansion. The fold changes are normalized to the corresponding levels in undifferentiated MSCs. The per-
centage changes of Col II (D), aggrecan (E), Col I (F) and Col X (G) levels as compared to initial culture (P3) at different passages after normal (line
with round dots) and selective (line with triangle dots) culture expansion are plotted simultaneously. All error bars represent standard deviation.
Statistical significance is determined by Student's t-test, * indicates p < 0.05.
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quantities of cells.57 Also, different from most active micro-
fluidic cell sorting techniques where external fields (electri-
cal, magnetic, acoustic, optical, etc.) are required to sort the
cells,58 our device requires only hydraulic pressure to operate,
making it easy to operate and scale-up. The large channel di-
mension (comparing to cell diameter) and fast sorting flow
rate of our spiral micro-channel device also minimizes the
risk of cell clogging, making it much more robust than con-
ventional size-based separation using cell filters.42
Conclusion
In summary, we identified a subpopulation of medium-size
(17–21 μm) “chondrogenic competent” MSCs from highly
heterogeneous total population of culture expanded MSCs.
We demonstrated that enriching this subpopulation of MSCs
during continuous culture expansion by repeated high-
throughput microfluidic exclusion of other subgroups
resulted in higher yield of MSCs with better chondrogenic po-
tential as compared to conventional expansion approach.
This approach enabled manipulation of culture expanded
MSCs towards “chondrogenic competent” state with mini-
mum biophysical and no additional biochemical stimulus,
which can greatly facilitate translation to clinical use. Al-
though this study primarily illustrated the use of microfluidic
subpopulation selection to produce large quantities of MSCs
with enhanced chondrogenic capacity, other therapeutic
needs of MSCs can potentially be fulfilled using similar
approach.
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